Physical space
  • Minimum conditions
    • Any location with capability for IM injections
    • Ease of access to a medical provider

Supply needs
  • Simple dressing (bandaid/2x2/tape)
  • Pulse oximeter
  • Blood pressure cuff
  • Stethoscope
  • Thermometer
  • Documentation capabilities

Staffing: RN capable of performing and monitoring an injection patient
Ordering EVUSHELD extended duration monoclonal antibodies *OUTPATIENT* for injection

• This is an open orderable drug to all providers
  • Currently ordered through paper documentation, available on toolkit
    • “Tixagevimab 150mg and Cilgavimab 150mg IM injection x 2”
      1. Ordering provider to document discussion regarding risks/benefits with patient and answer any clinical questions on order form
      2. Paper order to be faxed to CPH pharmacy 315-261-5513
      3. Orders will be reviewed by pharmacy for eligibility and to confirm drug availability
      4. Ordering office will be contacted with drug approval and dose will be delivered
      5. RN in office to confirm all patient’s questions have been answered, provide patient EUA fact sheet, review and document informed consent for an EUA drug

• Currently housed at CPH pharmacy, all doses will require couriering to outpatient offices

CPH pharmacy: 7a-7p week days, 7a – 4p weekends
Clinical Information - Contraindication/Unauthorized

• History of anaphylaxis to Evusheld or any of its excipients
• Active SARS-COV-2 infection
• Recent exposure to a COVID positive individual

• *Pregnancy/Lactation — there is insufficient data to evaluate drug risk should only be used if the potential benefits outweigh the potential risks for mother and child (pregnancy does not preclude use of Evusheld but should be considered with caution)
Clinical Information – Eligibility Criteria

• Age 18+ (or 12+ if >40kg in clinical coordination with pediatrician)

• Allergic reaction to previous dose of SARS-COV-2 vaccination

  OR

• Profound immune compromise or deficiency (innate or medication mediated)
Clinical Information – Adverse Reactions

• Allergic reactions
• Infusion site reactions
  • Pain
  • Burning
  • Bleeding
  • Infusion site infection
• May reduce immune function/increase risk for other infections
Documentation Criteria

• Negative COVID test
• Date and type of previously given SARS-COV-2 vaccination or why vaccination was deferred
• Reaction and severity to previous vaccination
• Diagnosis or medication causing immunocompromised/deficient status
Evusheld

Tixagevimab 150mg and Cilgavimab 150mg
Two IM injections
Storage

• Refrigerate unopened vials at 2C to 8C (36F to 46F) in the original carton to protect from light

• Do not freeze

• Do not shake

• Once each product is drawn up into a syringe it should be administered immediately as there are no preservatives

• Total time from vial puncture to administration cannot exceed 4hrs
Evusheld infusion solution should be administered by a qualified healthcare professional.

Materials for injection:
1. 3ml syringe x 2
2. Appropriate length and gauge administration needle for IM injection x 2
3. +/- drawing needle x 2

- Inspect each of the two vials, solution should be clear opalescent, colorless to slightly yellow (discard if solution is cloudy, discolored, or visible particles are seen)
- Withdraw 1.5mL of tixagevimab into a syringe
- Withdraw 1.5mL of cigavimab into a separate syringe
- Administer as an IM injection at two different sites, **gluteal muscles preferred**

Evusheld guidance recommended **1 HOUR OBSERVATION PERIOD**
• EUA Fact Sheet for PATIENTS
  • Evusheld Fact Sheet Patients

• EUA Fact Sheet for PROVIDERS
  • Evusheld Fact Sheet Providers
Warnings

• Hypersensitivity Including Anaphylaxis and Injection-Related Reactions
  • Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of Evusheld. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately appropriate medications and/or supportive therapy.

• Signs & Symptoms of Injection-Related Reactions:
  • Fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g., atrial fibrillation, tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vasovagal reactions (e.g., pre-syncope, syncope), dizziness, and diaphoresis